Ludwigshafen, September 15th, 2011 -- Phenex Pharmaceuticals AG announced today the start of a first-in-man Phase I study with its clinical drug candidate Px-102, a synthetic non-steroidal FXR agonist. The volunteers of the first
dose level received the drug and showed no signs of discomfort or other adverse effects. This
Phase I first-in-man study will be escalated from the initial dose over seven dose levels to obtain
information about the tolerance and pharmacokinetics of Px-102 in healthy volunteers. Following this
first Phase I study Phenex plans to run a multiple ascending dose Phase I study where the same
parameters will be observed during several days of multiple administrations. The Phase I studies for
Px-102 will be finished by early 2012. If all requirements are met, Phenex then plans to test Px-102
in a Phase II study in patients with Metabolic Syndrome and Non-Alcoholic Fatty Liver Disease
(NAFLD) to confirm if the potent therapeutic effects such as lipid lowering, improvement of insulin
sensitivity and reduction of markers for liver damage which were observed in several animal studies
can be reproduced in human patients
Px-102 is a potent, fully-synthetic and non-steroidal FXR agonist. The Farnesoid X Receptor (FXR)
is a bile acid receptor which when activated by Px-102 has a profound positive impact on
cholesterol, triglyceride and glucose metabolism in liver and intestine.
As was already demonstrated in several publications and Phenex-proprietary animal studies the
FXR agonist Px-102 potently reduces intestinal uptake of neutral lipids and cholesterol and at the
same time enhances the excretion of these lipid species. In addition, Px-102 improves hepatic
insulin sensitivity and shows massive hepatoprotective effects in animal models of liver cirrhosis or fibrosis. It is this combination of potent metabolic and liver protective effects that makes Px-102 an
ideal candidate for the treatment of Non-Alcoholic Steatohepatitis (NASH). Inflammation and
beginning fibrosis are the hallmarks in people with NASH-livers which affects a subset of individuals
who have developed a fatty liver due to an unhealthy lifestyle and overweight. The prevalence of
NASH is estimated to approach 5% of the total population in industrialized countries. NASH
markedly increases the likelihood to develop liver cancer or end stage liver cirrhosis. Currently there
is no approved therapy for NASH.
We aim at filling exactly this gap in medical treatment of liver diseases,“ says Dr. Claus Kremoser,
CEO of Phenex. “NASH and associated liver and metabolic diseases are on the rise and there is no
pharmacotherapy approved. Potent synthetic FXR-agonists such as Px-102 have the potential to
improve the overall metabolic state as well as the inflammatory and fibrotic changes in livers of
NASH patients. Next to the therapy of NASH itself, Px-102 may be well suited to treat related
diseases such as liver cirrhosis and fibrosis, Primary Biliary Cirrhosis (PBC) or Portal Hypertension.”
About Phenex Pharmaceuticals AG:
Phenex is a privately held drug discovery and development company headquartered in
Ludwigshafen with a research site in Heidelberg. The company focuses on novel attractive nuclear
receptor targets to develop innovative small molecule therapeutics in the fields of metabolic
syndrome / NASH and in autoimmune diseases.
Phenex´ most advanced program is Px-102, now at Phase I clinical stage, and it targets the nuclear
bile acid receptor FXR. This FXR agonist has unique properties in that it shows beneficial effects in
lipid lowering, in improving insulin sensitivity, in reducing body weight and in ameliorating the liver
inflammation and fibrosis that are hallmarks of Non-Alcoholic Steatohepatitis (NASH). NASH is a
metabolically induced liver disease with a worldwide prevalence of at least 25 million affected
individuals. If untreated, the disease can progress towards liver cirrhosis and liver failure or to
Hepatocellular Carcinoma (HCC). There is no approved treatment for NASH. Px-102 addresses this
medical need and represents a significant commercial opportunity.
Phenex´ second R&D program targets the nuclear receptor ROR?t. ROR?t inhibitors hold the
promise to become a new therapeutic approach in different autoimmune diseases with substantially
reduced side effects. This project is at lead optimisation status.
The company intends to develop its R&D programs up to a proof-of-concept study in humans in the
case of FXR and up to late preclinical stage in the case of ROR?t. At these stages the company will
seek partners from the pharmaceutical industry to license these molecules for further development.
Phenex is financed through three consecutive rounds of funding bringing the total equity raised to
17,2 million Euros. The circle of investors encompasses EVP Capital Partners/VRP, LBBW Venture,
Creathor Venture, KfW as well as private individuals and key persons from the pharmaceutical and
high-tech industry.
Visit our homepage at: http://www.phenex-pharma.com/